![Exact Sciences Corporation Website](https://cdn.finchat.io/28311.png)
Exact Sciences Corporation
NasdaqCM-EXAS
Company Overview
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Name
Exact Sciences Corporation
CEO
Mr. Kevin T. Conroy
Website
www.exactsciences.com
Sector
Biotechnology
Year Founded
1995
Profile
Market Cap
$10.92B
EV
$12.76B
Shares Out
184.77M
Revenue
$2,612.01M
Employees
6,550
Margins
Gross
73.19%
EBITDA
-2.64%
Operating
-10.81%
Pre-Tax
-6.59%
Net
-6.7%
FCF
-0.57%
Returns (5Yr Avg)
ROA
-9.3%
ROTA
-38.07%
ROE
-18.13%
ROCE
-10.19%
ROIC
-11.38%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$75.81
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$946.78M
Net Debt
$1,837.15M
Debt/Equity
0.87
EBIT/Interest
-12.01
Growth (CAGR)
Rev 3Yr
15.13%
Rev 5Yr
33.19%
Rev 10Yr
101.51%
Dil EPS 3Yr
-42.75%
Dil EPS 5Yr
-11.42%
Dil EPS 10Yr
1.85%
Rev Fwd 2Yr
13.56%
EBITDA Fwd 2Yr
53.71%
EPS Fwd 2Yr
—
EPS LT Growth Est
20%
Dividends
Yield
—
Payout
—
DPS
—
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
—